Overview

Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

After screening according to the criteria for selection and exclusion, patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation. The primary outcome is objective response rate (ORR).

Phase:

N/A

Details

Lead Sponsor:

The First Affiliated Hospital of Soochow University

Treatments:

Antibodies
Antibodies, Monoclonal
Azacitidine